These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 1106161)
1. L-Dopa and the treatment of extrapyramidal disease. Pelton EW; Chase TN Adv Pharmacol Chemother; 1975; 13():253-304. PubMed ID: 1106161 [No Abstract] [Full Text] [Related]
2. Propionic acidaemia with basal ganglia stroke: treatment of acute extrapyramidal symptoms with L-DOPA. Burlina AP; Baracchini C; Carollo C; Burlina AB J Inherit Metab Dis; 2001 Oct; 24(5):596-8. PubMed ID: 11757587 [TBL] [Abstract][Full Text] [Related]
3. [Interaction of L-DOPA and pyridoxine (a review of the literature)]. Uspenskiĭ AE Farmakol Toksikol; 1977; 40(6):722-33. PubMed ID: 340258 [No Abstract] [Full Text] [Related]
4. Letter: Extrapyramidal dementia and levodopa. Drachman DA; Stahl S Lancet; 1975 Apr; 1(7910):809. PubMed ID: 48039 [No Abstract] [Full Text] [Related]
5. Combination therapy of extrapyramidal disease with trihexyphenidyl and L-dopa: an electromyographic study with specific reference to tremor. Hökendorf H J Int Med Res; 1979; 7(1):19-28. PubMed ID: 421963 [TBL] [Abstract][Full Text] [Related]
6. Amantadine. Parkes D Adv Drug Res; 1974; 8():11-81. PubMed ID: 4219097 [No Abstract] [Full Text] [Related]
7. [Current medical treatment in the disorders of the extrapyramidal nervous system]. Rizzo PA; Morocutti A Clin Ter; 1975 Aug; 74(4):313-24. PubMed ID: 1227750 [No Abstract] [Full Text] [Related]
8. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease. Melamed E; Hefti F; Liebman J; Schlosberg AJ; Wurtman RJ Nature; 1980 Feb; 283(5749):772-4. PubMed ID: 6101905 [No Abstract] [Full Text] [Related]
9. [Comparison between EEG-finding and clinical picture in patients with Parkinsonism under L-dopa]. Bengesser G Wien Med Wochenschr; 1975 Feb; 125(7-8):120-1. PubMed ID: 1146347 [No Abstract] [Full Text] [Related]
10. Serotonin and Parkinson's disease. Hesselink JM Am J Psychiatry; 1993 May; 150(5):843-4. PubMed ID: 8480847 [No Abstract] [Full Text] [Related]
11. Management of the extrapyramidal manifestations of phenylketonuria with L-dopa. MacLeod MD; Munro JF; Ledingham JG; Farquhar JW Arch Dis Child; 1983 Jun; 58(6):457-8. PubMed ID: 6859941 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Kostrzewa RM; Kostrzewa JP; Brus R Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519 [TBL] [Abstract][Full Text] [Related]
14. [Clinical problems of extrapyramidal diseases]. Petelin LS Klin Med (Mosk); 1990 Sep; 68(9):10-3. PubMed ID: 2290310 [No Abstract] [Full Text] [Related]
15. The role of anticholinergic drugs in extra-pyramidal syndromes. Hunter KR Neuropharmacology; 1981 Dec; 20(12B):1315-7. PubMed ID: 6119641 [No Abstract] [Full Text] [Related]
16. [L-dopa treatment of Parkinson's disease]. Chen KM Taiwan Yi Xue Hui Za Zhi; 1971 Jul; 70(7):424-30. PubMed ID: 5293638 [No Abstract] [Full Text] [Related]
17. Approaches to the study of cerebral dopamine metabolism in certain extrapyramidal diseases. Barkhatova VP; Kandel' EI; Demina EG Neurosci Behav Physiol; 1985; 15(2):132-9. PubMed ID: 3160969 [No Abstract] [Full Text] [Related]
18. [Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor]. Jörg J Med Welt; 1979 Nov; 30(46):1740-2. PubMed ID: 537499 [No Abstract] [Full Text] [Related]
19. [Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry]. Bartholini G Schweiz Arch Neurol Neurochir Psychiatr; 1979; 125(2):265-9. PubMed ID: 45343 [TBL] [Abstract][Full Text] [Related]
20. [Clinical modification of cerebral palsy of the extrapyramidal type by L-dopa (Dopaflex)--longitudinal pilot study]. Grauel A Padiatr Grenzgeb; 1986; 25(5):383-7. PubMed ID: 3808723 [No Abstract] [Full Text] [Related] [Next] [New Search]